Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 222

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Erlotinib for Advanced Non–Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21

Open access
Wheatley-Price, Paul, Ding, Keyue, Seymour, Lesley, Clark, Gary M., Shepherd, Frances A.·2008·Journal of Clinical Oncology

Abstract

Purpose: National Cancer Institute of Canada Clinical Trials Group Study BR.21 established erlotinib as a standard of care in patients with non–small-cell lung cancer (NSCLC) after failure of first- or second-line chemotherapy. The current study analyzes the influence of age on outcomes in BR.21. Patients and Methods: BR.21 was a double-blind phase III trial that randomly assigned 731 patients to erlotinib 150 mg daily or placebo. End points included progression-free survival and overall survival (OS), response, quality of life (QOL), drug exposure, and toxicity, which are analyzed in this retrospective study by the following two age groups: ≥ 70 years (elderly) or less than 70 years (young). Results: There were 163 elderly patients (112 on erlotinib, 51 on placebo) and 568 young patients (376 on erlotinib, 192 on placebo). There was no significant difference between age groups randomly assigned to erlotinib or placebo in progression-free survival (elderly: 3.0 v 2.1 months; hazard ratio [HR] = 0.63; 95% CI, 0.44 to 0.90; P = .009; young: 2.1 v 1.8 months; HR = 0.64; 95% CI, 0.53 to 0.76; P < .0001; interaction, P = .77) or OS (elderly: 7.6 v 5.0 months; HR = 0.92; 95% CI, 0.64 to 1.34; P = .67; young: 6.4 v 4.7 months; HR = 0.73; 95% CI, 0.61 to 0.89; P = .0014; interaction, P = .31). Response rates were similar between age groups. Elderly patients, compared with young patients, had significantly more overall and severe (grade 3 and 4) toxicity (35% v 18%; P < .001), were more likely to discontinue treatment as a result of treatment-related toxicity (12% v 3%; P < .0001), and had lower relative dose-intensity (64% v 82% received > 90% planned dose; P < .001). Conclusion: Elderly patients treated with erlotinib gain similar survival and QOL benefits as younger patients but experience greater toxicity.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1200/jco.2007.15.2280

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Research works printed but not linked: 40

  1. 10.1634/theoncologist.12-1-20 · DOI · Paper page
  2. 10.1002/cncr.11380 · DOI · Paper page
  3. 10.1056/NEJM199912303412706 · DOI · Paper page
  4. 10.1200/JCO.2003.08.010 · DOI · Paper page
  5. 10.1136/bmj.311.7010.899 · DOI · Paper page
  6. 10.1200/JCO.2001.19.13.3210 · DOI · Paper page
  7. 10.1056/NEJMoa011954 · DOI · Paper page
  8. 10.1093/jnci/91.1.66 · DOI · Paper page
  9. 10.1093/jnci/95.5.362 · DOI · Paper page
  10. 10.1200/JCO.2007.12.5708 · DOI
  11. 10.1200/JCO.2005.07.172 · DOI · Paper page
  12. Fossella FV, Belani C: Phase III study (TAX 326) of docetaxel-cisplatin (DC) and docetaxel-carboplatin (DCb) versus vinorelbine-cisplatin (VC) for the first line treatment of advanced/metastatic non–small-cell lung cancer (NSCLC): Analyses in elderly patients. Proc Am Soc Clin Oncol 22:629a,2003, (abstr 2528) · doi:10.1016/s0169-5002(03)91709-0
  13. Langer C, Vangel M, Schiller J, et al: Age-specific subanalysis of ECOG 1594: Fit elderly patients (70-80 YRS) with NSCLC do as well as younger pts (<70). Proc Am Soc Clin Oncol 22:639a,2003, (abstr 2571) · doi:10.1016/s0169-5002(03)91707-7
  14. 10.1200/JCO.2005.00.224 · DOI · Paper page
  15. 10.1378/chest.128.2.947 · DOI
  16. 10.1093/jnci/94.3.173 · DOI · Paper page
  17. 10.1093/jnci/95.5.341 · doi:10.1093/jnci/95.5.341
  18. 10.1016/j.lungcan.2004.11.025 · doi:10.1016/j.lungcan.2004.11.025
  19. 10.1200/JCO.2004.08.163 · DOI · Paper page
  20. 10.1200/JCO.2000.18.10.2095 · DOI · Paper page
  21. 10.1200/JCO.2006.06.7835 · DOI
  22. 10.1093/jnci/92.3.205 · DOI · Paper page
  23. 10.3816/CLC.2006.s.004 · doi:10.3816/clc.2006.s.004
  24. 10.1200/JCO.2006.07.5754 · DOI · Paper page
  25. 10.1200/JCO.2006.05.8073 · DOI · Paper page
  26. 10.1200/JCO.1996.14.3.821 · DOI
  27. 10.1200/JCO.2006.09.5570 · doi:10.1200/jco.2006.09.5570
  28. 10.1038/sj.bjc.6601387 · DOI
  29. 10.1038/sj.bjc.6601470 · DOI
  30. 10.1158/1078-0432.CCR-06-0260 · DOI · Paper page
  31. 10.1158/1078-0432.CCR-07-0088 · DOI · Paper page
  32. 10.1124/dmd.105.007765 · DOI · Paper page
  33. 10.1016/S0009-9236(97)90166-1 · DOI · Paper page
  34. 10.2165/00003088-200544010-00002 · DOI · Paper page
  35. 10.1097/01.cad.0000203381.99490.ab · DOI
  36. 10.1097/01.JTO.0000283087.71346.19 · DOI
  37. Niho S, Ichinose Y, Tamura T, et al: Results of a randomized phase III study to compare the overall survival of gefitinib (IRESSA) versus docetaxel in Japanese patients with non–small-cell lung cancer who failed one or two chemotherapy regimens. J Clin Oncol 25:307s,2007, (suppl, abstr LBA7509) · DOI
  38. 10.1056/NEJMoa050736 · DOI · Paper page
  39. Shepherd FA, Ding K, Sakurada A, et al: Updated molecular analyses of exons 19 and 21 of the epidermal growth factor receptor (EGFR) gene and codons 12 and 13 of the KRAS gene in non-small cell lung cancer (NSCLC) patients treated with erlotinib in National Cancer Institute of Cancer. J Clin Oncol 25:402s,2007, (suppl; abstr 7571) · DOI
  40. 10.1055/s-2003-37149 · DOI

Cited by

See all 222

Metadata

Authors
Wheatley-Price, P., Ding, K., Seymour, L., Clark, G. M., & Shepherd, F. A.
Venue
Journal of Clinical Oncology
Published
2008-05-10
Volume
26
Issue
14
Pages
2350-2357
ISSN
  • 0732-183X (ISSN-L)
  • 1527-7755
OpenAlex
W2127685474
Cited by
222
References
2
FWCI
20.87
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Erlotinib for Advanced Non–Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. https://app.cochat.ai/papers/10.1200/jco.2007.15.2280
The paper
Wheatley-Price, P., Ding, K., Seymour, L., Clark, G. M., & Shepherd, F. A. (2008). Erlotinib for Advanced Non–Small-Cell Lung Cancer in the Elderly: An Analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2007.15.2280

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.